As I see it

Share this article:
The worst idea on Capitol Hill right now involves giving the FDA control of tobacco. The Family Smoking Prevention and Tobacco Control Act (HR 1108) passed the House Energy and Commerce Committee 38-12 in April and has the support of 218 congressmen and 56 senators, to say nothing of the more than 630 health, civic, church and youth organizations standing behind it.

With momentum like that, it seems unstoppable. When people rally behind a powerful, do-good idea like this, they seldom bother to consider “soft” negative practicalities, like the potential damage to the inner esprit de corps of the agency they're assigning their mission to.

In the FDA's case, internal morale is already at rock-bottom after more than two decades of political emasculation, resource reduction and unfunded new mandates from Congress. True, HR 1108 would be notionally self-funding through user fees and other charges on producers of tobacco products, but these revenues would take years to kick in.

In the meantime, the FDA would be organizationally disrupted, crippling overdue reforms in beleaguered areas of its core responsibilities—like drugs, medical devices and foods.

The last time Congress gave the FDA an assignment beyond its ken was in 1966, when it told the agency to regulate drugs of abuse. The FDA made such a mess of this that within two years Congress backtracked and drugs of abuse ended up in a brand-new agency, the Drug Enforcement Administration, in 1973.

The bill's goals are laudable, but the FDA is the wrong agency to implement those goals. Like the American lives it is charged with safeguarding, the FDA would be destroyed by tobacco.
Dickinson is editor of Dickinson's FDA Webview (fdaweb.com).
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in As I See It

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications